Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07805356) titled 'Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Condition:
Hypoparathyroidism
Chronic Hypoparathyroidism
Intervention:
Drug: Encaleret
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 31, 2026
Target Sample Size: 160
To know more, visit https://clinicaltrials.gov/st...